External Validation of the COVID-NoLab and COVID-SimpleLab Prognostic Tools.
Ann Fam Med
; 20(6): 548-550, 2022.
Article
in English
| MEDLINE | ID: covidwho-2140353
ABSTRACT
Our objective was to externally validate 2 simple risk scores for mortality among a mostly inpatient population with COVID-19 in Canada (588 patients for COVID-NoLab and 479 patients for COVID-SimpleLab). The mortality rates in the low-, moderate-, and high-risk groups for COVID-NoLab were 1.1%, 9.6%, and 21.2%, respectively. The mortality rates for COVID-SimpleLab were 0.0%, 9.8%, and 20.0%, respectively. These values were similar to those in the original derivation cohort. The 2 simple risk scores, now successfully externally validated, offer clinicians a reliable way to quickly identify low-risk inpatients who could potentially be managed as outpatients in the event of a bed shortage. Both are available online (https//ebell-projects.shinyapps.io/covid_nolab/ and https//ebell-projects.shinyapps.io/COVID-SimpleLab/).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal:
Ann Fam Med
Journal subject:
Family Practice
Year:
2022
Document Type:
Article
Affiliation country:
Afm.2872
Similar
MEDLINE
...
LILACS
LIS